A carregar...
Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?
Immune checkpoint inhibitors (ICIs) are beginning to show promise in the clinical management of hepatocellular carcinoma (HCC). Most recently, the anti-programmed death protein-1 (PD-1) agent atezolizumab combined with bevacizumab demonstrated superiority to sorafenib in a Phase 3 randomised clinica...
Na minha lista:
| Publicado no: | Vaccines (Basel) |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7711845/ https://ncbi.nlm.nih.gov/pubmed/33023131 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines8040578 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|